Steven Cohen Bei Gene, Ltd. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 667,166 shares of BGNE stock, worth $123 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
667,166
Previous 381,382
74.93%
Holding current value
$123 Million
Previous $54.4 Million
175.28%
% of portfolio
0.41%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.94 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.18 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$952 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$914 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$681 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...